Table 2.
SIRs of all malignancies in thiopurine users, stratified by sex and age.
| Male |
Female |
Total |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Age group | Observed no. | Expected no. | SIR (95% CI) | Observed no. | Expected no. | SIR (95% CI) | Observed no. | Expected no. | SIR (95% CI) | Crude incidence rate (per 100,000 population) |
| 18–44 | 53 | 8.13 | 6.52 (4.98–8.53) | 100 | 27.5 | 3.64 (2.99–4.43) | 153 | 35.6 | 4.30 (3.67–5.04) | 4625.2 |
| 45–64 | 167 | 55.6 | 3.00 (2.58–3.49) | 196 | 93.3 | 2.10 (1.83–2.42) | 363 | 148.9 | 2.44 (2.20–2.70) | 11,932.9 |
| 65+ | 83 | 54.5 | 1.52 (1.23–1.89) | 85 | 57.8 | 1.47 (1.19–1.82) | 168 | 112.3 | 1.50 (1.29–1.74) | 15,245.0 |
| Sum | 303 | 118.3 | 2.56 (2.28–2.86) | 381 | 178.7 | 2.13 (1.92–2.35) | 684 | 297.1 | 2.30 (2.13–2.48) | 9178.7 |
CI, confidence interval; SIR, standardized incidence ratio.